Kubel M, Helbig W, Schwenke H, Wötzel M, Thierbach V, Standke E, Hoffmann F A
Bone Marrow Transplantation Centre, Karl-Marx-Universität, Leipzig, GDR.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(3-4):493-8.
In order to assess the clinical advantage of autologous bone marrow transplantation (ABMT) without ex vivo purging, the results in 26 patients (10 AML, 16 ALL) in 1. CR were analyzed retrospectively. All patients received 3 consolidation cycles "in-vivo purging" before marrow harvesting. Beside relapses infections and cardiac failure were the most frequent complications. After 1 to 12.5 months 11 cases relapsed with a higher probability in patients who had a longer period of induction and between CR and ABMT. 12 patients became relapse-free survivors 6 to 53 months after ABMT with a stable plateau after 12.5 months for 8 patients. In conclusion, ABMT following "in-vivo purging" as the strongest one-step postremission therapy in patients with acute leukaemias may be a way for better long-term results in these patients.
为了评估未进行体外净化的自体骨髓移植（ABMT）的临床优势，对26例处于完全缓解（CR）1期的患者（10例急性髓系白血病、16例急性淋巴细胞白血病）的结果进行了回顾性分析。所有患者在采集骨髓前均接受了3个巩固周期的“体内净化”。除复发外，感染和心力衰竭是最常见的并发症。1至12.5个月后，11例患者复发，诱导期较长以及CR期与ABMT期间隔较长的患者复发概率更高。12例患者在ABMT后6至53个月成为无复发生存者，8例患者在12.5个月后出现稳定的平台期。总之，对于急性白血病患者，“体内净化”后的ABMT作为最强的一步缓解后治疗方法，可能是使这些患者获得更好长期结果的一种方式。
